Get the Stockscreener App
0.1683
17.04%
0.0245
Genprex Inc stock is traded at $0.1683, with a volume of 96.93M.
It is up +17.04% in the last 24 hours and down -36.97% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.1438
Open:
$0.1706
24h Volume:
96.93M
Relative Volume:
47.17
Market Cap:
$5.58M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0144
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
-20.69%
1M Performance:
-36.97%
6M Performance:
-57.19%
1Y Performance:
-75.96%
1-Day Range:
$0.1566
$0.1887
1-Week Range:
$0.14
$0.2499
52-Week Range:
$0.14
$3.97
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.1683 | 6.39M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Trend analysis for Genprex Inc. this weekEarnings Overview Summary & AI Driven Stock Movement Reports - Newser
Is Genprex Inc. forming a bottoming base2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - Newser
Visual trend scoring systems applied to Genprex Inc.IPO Watch & Target Return Focused Picks - Newser
Genprex Inc. stock daily chart insights2025 Valuation Update & High Accuracy Trade Alerts - Newser
Leading vs lagging indicators on Genprex Inc. performanceQuarterly Performance Summary & Community Trade Idea Sharing Platform - Newser
Earnings visualization tools for Genprex Inc.Earnings Risk Summary & Reliable Trade Execution Plans - Newser
Exit strategy if you’re trapped in Genprex Inc.Weekly Trade Summary & AI Optimized Trading Strategy Guides - Newser
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers - Eastern Progress
What MACD signals say about Genprex Inc.July 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
Published on: 2025-08-19 14:58:20 - Newser
Has Genprex Inc. formed a bullish divergenceAnalyst Upgrade & Accurate Intraday Trade Tips - Newser
Predicting Genprex Inc. trend using moving averagesWeekly Trend Report & AI Enhanced Execution Alerts - Newser
Technical analysis overview for Genprex Inc. stockJuly 2025 Snapshot & High Accuracy Trade Alerts - Newser
News impact scoring models applied to Genprex Inc.Quarterly Growth Report & AI Forecast Swing Trade Picks - Newser
Statistical indicators supporting Genprex Inc.’s strengthMarket Risk Analysis & Long-Term Safe Investment Plans - Newser
How to manage a losing position in Genprex Inc.Portfolio Value Report & Risk Adjusted Swing Trade Ideas - Newser
Genprex Secures Patent Allowances for Gene Therapy - MSN
How to build a custom watchlist for Genprex Inc.July 2025 Outlook & Fast Entry and Exit Trade Plans - Newser
Genprex Secures US, EU Patents for its Oncology Drug Reqorsa - Mexico Business News
Genprex receives notice of allowance for multiple patents for Reqorsa - TipRanks
Genprex Says US, EU Issue Patent Allowances for Reqorsa Combination Therapies - MarketScreener
Genprex receives patent allowances for cancer therapy combinations - Investing.com
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa Gene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers - AInvest
Patent Protection Until 2037: Genprex Strengthens Reqorsa Cancer Therapy IP Portfolio Globally - Stock Titan
Comparing Genprex Inc. in custom built stock radarsWeekly Trade Report & Free High Accuracy Swing Entry Alerts - Newser
Why Genprex Inc. stock attracts strong analyst attentionJuly 2025 Summary & Expert Verified Movement Alerts - thegnnews.com
Is Genprex Inc. stock reversal real or fakeEarnings Trend Report & Growth Focused Stock Pick Reports - Newser
Is Genprex Inc. stock suitable for long term investingWeekly Profit Summary & Scalable Portfolio Growth Ideas - thegnnews.com
Is Genprex Inc. stock bottoming outPortfolio Value Summary & Stepwise Swing Trade Plans - Newser
Will Genprex Inc. stock benefit from interest rate changesForecast Cut & Precise Buy Zone Identification - Newser
Genprex Inc. stock trend forecastTrade Volume Summary & Risk Controlled Stock Pick Alerts - Newser
Using fundamentals and technicals on Genprex Inc.Forecast Cut & AI Forecast Swing Trade Picks - Newser
Genprex Stockholders Approve Key Proposals at Annual Meeting - MSN
Price action breakdown for Genprex Inc.Market Performance Report & Weekly Stock Performance Updates - Newser
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):